Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
Express Scripts
Mallinckrodt
Johnson and Johnson

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR NUEDEXTA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nuedexta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01630811 ↗ Nuedexta for the Treatment of Adults With Autism Completed Sutter Health Phase 2 2012-01-24 Primary: Demonstrate reduced frequency and intensity of maladaptive behaviors as measured by the Aberrant Behavior Checklist (ABC) Irritability subscale in subjects given Nuedexta 8 weeks over subjects given placebo. Secondary: Demonstrate a trend towards reduced aggressive behavior as measured by Overt Aggression Scale (OAS).
NCT01799941 ↗ Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed OptumInsight Life Sciences Phase 4 2013-02-01 The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with prevalent conditions such as dementia, stroke, and traumatic brain injury (TBI)over a 12 week period.
NCT01799941 ↗ Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed Avanir Pharmaceuticals Phase 4 2013-02-01 The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with prevalent conditions such as dementia, stroke, and traumatic brain injury (TBI)over a 12 week period.
NCT01806857 ↗ Clinical Trial Nuedexta in Subjects With ALS Completed ALS Association Phase 2 2013-04-01 The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).
NCT01806857 ↗ Clinical Trial Nuedexta in Subjects With ALS Completed State University of New York - Upstate Medical University Phase 2 2013-04-01 The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).
NCT01806857 ↗ Clinical Trial Nuedexta in Subjects With ALS Completed Center for Neurologic Study, La Jolla, California, Phase 2 2013-04-01 The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nuedexta

Condition Name

Condition Name for Nuedexta
Intervention Trials
Major Depressive Disorder 3
Pseudobulbar Affect (PBA) 2
Autism 1
Dementia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nuedexta
Intervention Trials
Depressive Disorder, Major 3
Depressive Disorder 3
Depression 3
Motor Neuron Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nuedexta

Trials by Country

Trials by Country for Nuedexta
Location Trials
United States 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nuedexta
Location Trials
Florida 3
New York 2
Ohio 2
California 2
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nuedexta

Clinical Trial Phase

Clinical Trial Phase for Nuedexta
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nuedexta
Clinical Trial Phase Trials
Completed 6
Terminated 2
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nuedexta

Sponsor Name

Sponsor Name for Nuedexta
Sponsor Trials
Avanir Pharmaceuticals 4
ALS Association 2
The University of Texas Health Science Center, Houston 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nuedexta
Sponsor Trials
Other 15
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Merck
McKesson
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.